BioMaxima SA
WSE:BMX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioMaxima SA
Capital Expenditures
BioMaxima SA
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioMaxima SA
WSE:BMX
|
Capital Expenditures
-zł2.3m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mercator Medical SA
WSE:MRC
|
Capital Expenditures
-zł40.3m
|
CAGR 3-Years
32%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-5%
|
|
|
P
|
PZ Cormay SA
WSE:CRM
|
Capital Expenditures
-zł2.5m
|
CAGR 3-Years
33%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
BioMaxima SA
Glance View
Biomaxima SA operates in the field of biotechnology and laboratory diagnostics. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2010-06-08. The company manufactures and distributes reagents and equipment for the laboratory diagnosis. The company produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The firm supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
See Also
What is BioMaxima SA's Capital Expenditures?
Capital Expenditures
-2.3m
PLN
Based on the financial report for Dec 31, 2024, BioMaxima SA's Capital Expenditures amounts to -2.3m PLN.
What is BioMaxima SA's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-7%
Over the last year, the Capital Expenditures growth was 87%. The average annual Capital Expenditures growth rates for BioMaxima SA have been 20% over the past three years , -7% over the past five years .
